News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
150 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38485)
2025 (25218)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3635)
June (2415)
July (2091)
August (2652)
September (2458)
October (418)
Day
1 (150)
2 (126)
3 (96)
5 (29)
6 (17)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
Day
1
2
3
5
6
Approvals
Novartis Secures First FDA Approval of Oral BTK Inhibitor for Chronic Hives
The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients who still show symptoms after antihistamine treatment.
October 1, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access
At the heart of the agreement is Pfizer’s $70 billion commitment to U.S.-based manufacturing and an exemption from tariffs for three years. While the reaction was mostly positive from Wall Street, other observers noted that the benefits for patients are unclear at best.
October 1, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
October 1, 2025
·
4 min read
Press Releases
Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
October 1, 2025
·
4 min read
Press Releases
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
October 1, 2025
·
7 min read
Press Releases
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares
October 1, 2025
·
6 min read
Press Releases
Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors
October 1, 2025
·
2 min read
Press Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 30, 2025
October 1, 2025
·
1 min read
Press Releases
Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases
October 1, 2025
·
6 min read
Press Releases
Stephenson Global Prize Awards $1 Million to Dr. Frank McCormick for Innovation in Pancreatic Cancer Research
October 1, 2025
·
4 min read
Previous
2 of 15
Next
